IC
RETA

Ikarian Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Ikarian Capital’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-201,200
Closed -$7.64M – 135
2022
Q4 		$7.64M Buy
201,200
+182,800
+993% +$6.29M 1.84% 17
2022
Q3 		$463K Buy
+18,400
New +$510K 0.09% 86
2022
Q2 		– Sell
-649,600
Closed -$21.3M – 217
2022
Q1 		$21.3M Buy
649,600
+549,600
+550% +$16.3M 2.8% 7
2021
Q4 		$2.64M Sell
100,000
-371,400
-79% -$28.7M 0.39% 55
2021
Q3 		$47.4M Buy
471,400
+296,500
+170% +$34.8M 3.34% 3
2021
Q2 		$24.8M Buy
174,900
+70,000
+67% +$7.9M 2% 8
2021
Q1 		$10.5M Sell
104,900
-61,700
-37% -$7.2M 0.35% 63
2020
Q4 		$20.6M Buy
166,600
+109,200
+190% +$14.4M 0.91% 20
2020
Q3 		$5.59M Sell
57,400
-26,300
-31% -$3.29M 0.4% 63
2020
Q2 		$13.1M Sell
83,700
-41,300
-33% -$6.28M 1.04% 31
2020
Q1 		$18M Buy
+125,000
New +$24.1M 1.36% 17

Other funds holding RETA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ikarian Capital's RETA Position: Q3 2023 in Review

Ikarian Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 5,472 shares — an estimated $558K sold.

Ikarian Capital first reported a position in RETA in Q1 2021 and held it in 6 quarters. The position peaked at $7.32M in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • Ikarian Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Ikarian Capital sold 5,472 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $558K.
  • Ikarian Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 6 quarters.
  • Ikarian Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $7.32M in Q1 2023.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.